je.st
news
FDA Approves Mercks LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
2013-05-03 21:06:15| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia, as an Adjunct to Diet When Diet Alone Is Not Enough Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: product
lower
cholesterol
fda
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||